387 related articles for article (PubMed ID: 37424859)
1. Lean nonalcoholic fatty liver disease and sarcopenia.
Chen M; Cao Y; Ji G; Zhang L
Front Endocrinol (Lausanne); 2023; 14():1217249. PubMed ID: 37424859
[TBL] [Abstract][Full Text] [Related]
2. The Association of Sarcopenia and Visceral Obesity with Lean Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus.
Zhang X; He Z; Si Q; Hu X; Yang L; Gu X; Du L; Wang L; Pan L; Li Y; Li J; Yang B; Gu X
J Diabetes Res; 2022; 2022():2229139. PubMed ID: 36387941
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution.
Alferink LJM; Trajanoska K; Erler NS; Schoufour JD; de Knegt RJ; Ikram MA; Janssen HLA; Franco OH; Metselaar HJ; Rivadeneira F; Darwish Murad S
J Bone Miner Res; 2019 Jul; 34(7):1254-1263. PubMed ID: 31074909
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity.
Wijarnpreecha K; Panjawatanan P; Aby E; Ahmed A; Kim D
Maturitas; 2019 Jun; 124():48-54. PubMed ID: 31097179
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity.
Han E; Kim MK; Im SS; Jang BK; Kim HS
J Diabetes Complications; 2022 Aug; 36(8):108253. PubMed ID: 35817677
[TBL] [Abstract][Full Text] [Related]
6. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).
Lee YH; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH
Hepatology; 2016 Mar; 63(3):776-86. PubMed ID: 26638128
[TBL] [Abstract][Full Text] [Related]
8. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.
Iwaki M; Kobayashi T; Nogami A; Saito S; Nakajima A; Yoneda M
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839249
[TBL] [Abstract][Full Text] [Related]
9. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
Mikolasevic I; Pavic T; Kanizaj TF; Bender DV; Domislovic V; Krznaric Z
Can J Gastroenterol Hepatol; 2020; 2020():8859719. PubMed ID: 33204675
[TBL] [Abstract][Full Text] [Related]
11. Interaction between sarcopenia and nonalcoholic fatty liver disease.
Joo SK; Kim W
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S68-S78. PubMed ID: 36472051
[TBL] [Abstract][Full Text] [Related]
12. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease.
Gan D; Wang L; Jia M; Ru Y; Ma Y; Zheng W; Zhao X; Yang F; Wang T; Mu Y; Zhu S
Clin Nutr; 2020 Apr; 39(4):1124-1130. PubMed ID: 31053512
[TBL] [Abstract][Full Text] [Related]
13. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.
Li N; Xang W; Wu S; Li D; Chang M; Xie C; Zhang MY; Tan H
Front Endocrinol (Lausanne); 2023; 14():1173757. PubMed ID: 37435491
[TBL] [Abstract][Full Text] [Related]
14. Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity.
Kim HK; Bae SJ; Lee MJ; Kim EH; Park H; Kim HS; Cho YK; Jung CH; Lee WJ; Choe J
Clin Mol Hepatol; 2023 Oct; 29(4):987-1001. PubMed ID: 37403320
[TBL] [Abstract][Full Text] [Related]
15. Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people.
Zhu X; Huang Q; Ma S; Chen L; Wu Q; Wu L; Ma H; Li X; Li Q; Aleteng Q; Hu Y; He W; Gao J; Lin H; Tang H; Gao X; Xia M
Hepatol Int; 2023 Apr; 17(2):313-325. PubMed ID: 36327053
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenic obesity in fatty liver.
Merli M; Lattanzi B; Aprile F
Curr Opin Clin Nutr Metab Care; 2019 May; 22(3):185-190. PubMed ID: 30893090
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.
Polyzos SA; Vachliotis ID; Mantzoros CS
Metabolism; 2023 Oct; 147():155676. PubMed ID: 37544590
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?
De Fré CH; De Fré MA; Kwanten WJ; Op de Beeck BJ; Van Gaal LF; Francque SM
Obes Rev; 2019 Feb; 20(2):353-363. PubMed ID: 30474288
[TBL] [Abstract][Full Text] [Related]
19. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
Akyuz U; Yesil A; Yilmaz Y
Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
[TBL] [Abstract][Full Text] [Related]
20. [Research advances in the relationship between nonalcoholic fatty fiver disease and sarcopenia].
Yu R; Shi QW; Wang CF; Chen LD; Zhang LF
Zhonghua Gan Zang Bing Za Zhi; 2019 Sep; 27(9):725-727. PubMed ID: 31594102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
